JAYLIN MILLER: Open Payments
NPI 1912421553 · IOWA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 41 payments from 15 companies in 2025. Trend: 2023 $157 · 2024 $462 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| PFIZER INC. | 3 | $88 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Novo Nordisk Inc | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
Products named: CAPLYTA, TRINTELLIX, NURTEC ODT, Auvelity, VRAYLAR, UBRELVY, FANAPT, QULIPTA.
Industry payments across LA — which companies pay providers there.
